GTx Inc. (NASDAQ:GTXI) was the target of a significant increase in short interest during the month of September. As of September 15th, there was short interest totalling 1,242,509 shares, an increase of 66.5% from the August 31st total of 746,408 shares. Approximately 3.1% of the shares of the company are sold short. Based on an average trading volume of 1,200,641 shares, the short-interest ratio is presently 1.0 days.
An institutional investor recently raised its position in GTx stock. BVF Inc. IL increased its stake in GTx Inc. (NASDAQ:GTXI) by 3.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,512,000 shares of the biopharmaceutical company’s stock after buying an additional 348,864 shares during the period. GTx comprises 1.4% of BVF Inc. IL’s holdings, making the stock its 21st largest position. BVF Inc. IL owned about 8.12% of GTx worth $5,756,000 as of its most recent filing with the SEC. 10.77% of the stock is owned by hedge funds and other institutional investors.
GTx (NASDAQ:GTXI) opened at 0.75 on Wednesday. The stock’s 50 day moving average is $0.68 and its 200-day moving average is $0.64. The stock has a market capitalization of $106.44 million, a price-to-earnings ratio of 4.52 and a beta of 2.35. GTx has a 12 month low of $0.29 and a 12 month high of $1.17.
GTx (NASDAQ:GTXI) last released its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.01. On average, equities research analysts expect that GTx will post ($0.12) earnings per share for the current year.
GTXI has been the topic of a number of research reports. Jefferies Group lowered their target price on shares of GTx from $0.75 to $0.50 and set a “hold” rating on the stock in a research report on Wednesday, August 10th. Zacks Investment Research upgraded shares of GTx from a “sell” rating to a “hold” rating in a research report on Tuesday, July 12th.
GTx Company Profile
GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).
Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.